Evangelista, Marie

Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants

Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science

Fungal and yeast genetics researchBioinformatics and Genomic Networks

Cited by 2,138

A Specificity Map for the PDZ Domain Family

Tonikian, R., Zhang, Y., Sazinsky, S. L., Currell, B., Yeh, J.-H., Reva, B., Held, H. A., Appleton, B. A., Evangelista, M., Wu, Y., et al. (2008) · PLoS Biology

Protein Structure and DynamicsChemical Synthesis and Analysis

Cited by 476

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences

Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 398

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation

Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research

Cancer Cells and MetastasisCancer, Hypoxia, and Metabolism

Cited by 307

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition

Boudreau, A., Purkey, H. E., Hitz, A., Robarge, K., Peterson, D., Labadie, S., Kwong, M., Hong, R., Gao, M., Del Nagro, C., et al. (2016) · Nature Chemical Biology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 280

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer

Hippo pathway signaling and YAP/TAZMicrotubule and mitosis dynamics

Cited by 215

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 183

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Julian, C., Pal, N., Gershon, A., Evangelista, M., Purkey, H., Lambert, P., Shi, Z., & Zhang, Q. (2023) · BMC Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 31

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS G12C inhibitors

Feng, S., Callow, M. G., Fortin, J.-P., Khan, Z., Bray, D., Costa, M., Shi, Z., Wang, W., & Evangelista, M. (2022) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 27

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

Williams, B., Taylor, A., Orozco, O., Owen, C., Kelley, E., Lescarbeau, A., Shortsleeves, K., Kipp, R., Nguyen, V., Brophy, E., et al. (2022) · Cancer Research

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 7